WO1998049325A1 - Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport - Google Patents

Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport Download PDF

Info

Publication number
WO1998049325A1
WO1998049325A1 PCT/CA1998/000385 CA9800385W WO9849325A1 WO 1998049325 A1 WO1998049325 A1 WO 1998049325A1 CA 9800385 W CA9800385 W CA 9800385W WO 9849325 A1 WO9849325 A1 WO 9849325A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
gfp
proteins
reporter
nuclear
Prior art date
Application number
PCT/CA1998/000385
Other languages
French (fr)
Inventor
Ursula Stochaj
Original Assignee
Mcgill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcgill University filed Critical Mcgill University
Priority to AU70229/98A priority Critical patent/AU7022998A/en
Publication of WO1998049325A1 publication Critical patent/WO1998049325A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Definitions

  • the invention relates to reporter fusion proteins which allow the monitoring of facilitated transport and passive diffusion of proteins across the nuclear envelope in mammalian cells, cloning and expression vectors encoding these reporter proteins and transfected cell lines thereof.
  • NLSs nuclear . localization sequences
  • the nuclear pore complex mediates also diffusion, and proteins of molecular masses of 40kD or less can enter the nucleus via passive diffusion. By contrast, proteins that exceed the size of the diffu- sion channel enter the nucleus by a facilitated process that requires energy and a NLS. Polypeptides larger than 70kD are excluded from nuclei if they do not carry a functional NLS. NLSs can be divided into several classes. The NLS present in SV40 T-antigen is an exam- pie for a "simple" NLS containing a stretch of basic amino acid residues.
  • a second class of NLSs contains "bipartite" sequences that carry two clusters of posi- tively charged amino acid residues that are separated by a spacer region, such as the NLS of Xenopus laevis nucleoplasmin.
  • Another type of targeting sequences includes complex NLSs which do not fit into the classes of simple or bipartite signals.
  • GFP Aequorea victoria green fluorescent protein
  • SV40*-NLS mutant form of SV40-NLS SV40inv-NLS inverse sequence of SV40-NLS To analyze nucleocytoplasmic traffic in growing cells, an experimental system which is based on the inducible synthesis of fluorescent reporter proteins was developed. Reporter proteins of various sizes described here carry different NLSs which are fused to the Aequorea victoria green fluorescent protein (GFP). These substrates were expressed and localized in mammalian culture cells. In addition to the analysis of facilitated protein transport into nuclei, assays to study passive diffusion from the nucleus into the cytoplasm were described. To facilitate the generation of gene fusions that encode different mutants of GFP with or without a nuclear localization sequence several new cloning vectors were generated.
  • a stable cell line that produces a nuclear reporter protein under control of an inducible promoter was analyzed. Upon induction, single cells of this clone synthesize similar amounts of the reporter pro- tein.
  • such cell lines offer the advantage that large numbers of cells can be tested simultaneously under identical conditions. Additional stable cell lines are currently generated for more detailed analyses of transport and diffusion across the nuclear envelope. Taken together, novel experimental tools to investigate nucleocytoplasmic transport and diffusion in intact mammalian cells were described.
  • tagged nuclear transport substrates carrying various numbers of GFP to study nucleocytoplasmic traffic in vi tro were also generated. These substrates can be expressed in Escherichia coli and purified by metal affinity-chromatography . The purified substrates are currently tested with semi-permeabilized HeLa cells and with yeast spheroplasts to demonstrate that these proteins are bona fide substrates for nuclear transport.
  • genes encoding reporter proteins to monitor transport and passive diffusion of proteins across the nuclear envelope in mammalian cells which comprises a protein carrying a nuclear localization sequence (NLS) fused to at least one copy of a reporter protein, wherein the reporter protein allows for the visualization of the reporter fusion protein.
  • NLS nuclear localization sequence
  • the NLS derived from SV40 T-antigen is connected to the reporter protein via a linker sequence encoding small amino acid residues.
  • the NLS may also be derived from Xenopus laevis nucleoplasmin or present in the C-terminal portion of nucleoplasmin.
  • an expression vector to transiently and stably express reporter genes of the present invention which comprises a gene encoding a protein carrying a nuclear localization sequence (NLS) fused to at least one copy of a reporter protein, wherein expression of the gene is under the control of an inducible promoter.
  • NLS nuclear localization sequence
  • the NLS may be connected to the reporter protein via a linker sequence encoding small amino acid residues.
  • the reporter protein may be any fluorescent protein such as Aequorea vi ctoria green fluorescent protein (GFP).
  • GFP green fluorescent protein
  • a cell line stably expressing a nuclear reporter protein to monitor trans- port and passive diffusion of proteins across the nuclear envelope, which comprises a cell line trans- fected by the expression vector of the present invention.
  • the NLS may be fused to the reporter protein by a linker encoding small amino acid residue.
  • the cell lines may be selected from the group consisting of HeLa, COS and CHO.
  • an in vivo assay for screening compounds which affect transport and/or passive diffusion of proteins across the nuclear envelope in mammalian cells which comprises the steps of: a) treating a stably transfected cell line of the present invention with a compound; and b) visualizing the distribution of reporter protein in nuclei and cytoplasm.
  • an in vi tro assay for screening compounds which affect transport and/or passive diffusion of proteins across the nuclear envelope in mammalian cells which comprises the steps of: a) treating semi-permeabilized cells which support in vitro nuclear transport with a compound and a pro- tein of the present invention; and b) visualizing the distribution of reporter protein in nuclei and cytoplasm.
  • the cells may be treated with the compound and protein concurrently or one after the other.
  • Fig. 1 illustrates a schematic representation of different fluorescent reporter proteins containing GFP used in this study
  • Fig. 2 illustrates transient expression of fusion proteins harboring one copy of GFP
  • Fig. 3 illustrates transient expression of transport substrates with two and four copies of GFP
  • Fig. 4 illustrates the effect of linker sequences on the localization of SV40-GFP4;
  • Fig. 5 illustrates the localization of reporter proteins harboring wild type and mutant versions of SV40-NLS
  • Figs. 6A and 6B illustrate nucleocytoplasmic diffusion of NP-GFP, (A) chilling of cells, (B) treatment with sodium azide/deoxyglucose at different temperatures ;
  • Fig. 7 illustrates the kinetics of the diffusion of NP-GFP across the nuclear envelope in HeLa cells treated with sodium azide/deoxyglucose
  • Fig. 8 illustrates stably transfected HeLa cells expressing nucleoplasmin-GFP.
  • an experimental system to study nucleocytoplasmic traffic of proteins in living mammalian cells.
  • substrates were generated that contain one or more copies of Aequorea victoria green fluorescent protein (GFP).
  • GFP Aequorea victoria green fluorescent protein
  • Reporter proteins of various sizes that carry different nuclear localization sequences (NLSs) were created to follow facilitated transport and passive diffusion across the nuclear envelope.
  • the expression of reporter genes was controlled by an inducible promoter.
  • Transiently and stably transfected HeLa cells were employed to follow the sorting of fluorescent reporter proteins.
  • NLS-GFP fusions were located in HeLa cells it was found that direct fusion of the NLS derived from SV40 T-anti- gen to GFP prevented nuclear accumulation of the protein.
  • insertion between NLS and GFP of different linkers encoding small amino acid residues produced reporter proteins that were competent for nuclear import.
  • a small protein of approximately 30kD that harbors one copy of GFP and the bipartite Xenopus nucleoplasmin NLS accumulates effi- ciently in nuclei of HeLa cells. Under conditions which abolish active facilitated nuclear transport the protein diffuses across the nuclear envelope.
  • This polypeptide can therefore be used as a reporter to analyze passive diffusion between nucleus and cyto- plasm.
  • histidine tagged versions of reporter proteins which permits their purification by metal affinity chromatography were also generated.
  • HtTA-1 cells are described in detail in Damke et al., 1995 (Damke, H. et al . , 1995, Meth . Enzym. ,
  • HtTA-1 cells contain the tTA-element which permits the control of gene expression by addi- tion of tetracycline to the growth medium.
  • HeLa cells were grown in Dulbecco's modified essential medium (DMEM) containing penicillin G (50U/ml), streptomycin (50 ⁇ g/ml) and 8 % fetal bovine serum (complete medium).
  • DMEM Dulbecco's modified essential medium
  • HtTA-1 cells were grown and transfected as described above. Transfected cells were grown under standard conditions for at least two weeks without selection. One day after addition of 50 nM dexametha- sone, cells were sorted by FACS into 24-well plates under sterile conditions . A maximum of one cell per well was obtained after sorting. Cells were further grown for two to three weeks and analyzed for the synthesis of nuclear reporter proteins. Towards this end, stable cell lines were kept in the presence of 50 nM dexamethasone ( 2 days ) and analyzed by fluorescence microscopy as described above. Plasmid constructions
  • Plasmid pGRE5-2 was used as a vector for genes encoding different fluorescent substrates. Gene expression is controlled by glucocorticoid response elements and can be induced by dexamethasone (Mader, S and White, J., 1993, Proc . Na tl . Acad. Sci USA, 90:5603- 5607). A mutant version of GFP in pBluescriptKS "1" carry- ing a Ser65 —> Thr65 substitution by PCR-amplification of the GFP-DNA using appropriate primers was generated. This created plasmid p580 which contains the mutant GFP allele cloned into the KpnI/EcoRI sites of pBluescript
  • Plasmids encoding nuclear substrates with one or two copies of GFP Plasmids encoding nuclear substrates with one or two copies of GFP
  • Nucleoplas- min-GFP i.e., the C-terminal half of Xenopus nucleo- plasmin fused to a single copy of GFP has been described (Chatterjee, S. and Stochaj , U., 1996, BioTechniques, 21: 62-63).
  • Plasmid p709 is derived from pGRE5-2 and codes for NP-GFP. Gene fusions containing two copies of GFP were created by removal of the UAG stop codon of GFP followed by insertion of a NotI linker (12mer, New England Biolabs). In addition, a Notl-linker was inserted into the KpnI-site of plasmid p580. Both copies of the GFP coding sequence were fused in frame via their Notl-sites thereby creating GFP2 in pBluescript (plasmid p690). Insertion of the KpnI/EcoRI fragment of p690 into the KpnI/EcoRI sites of pGRE5-2 created plasmid p785. For p785, the expression of GFP2 is driven by an inducible promoter carrying 5 glucocor- ticoid response elements. Plasmids encoding fusion proteins containing four copies of GFP
  • DNAs encoding different NLSs were cloned into pGRE5-2. These vectors were digested with Xhol and
  • DNA was digested with Xhol and
  • Agel Recessed ends were filled in and DNA was autoli- gated.
  • Derivatives of plasmids carrying wild type or mutant versions of SV40- NLS fused to GFP4 were generated by in frame insertion of linker sequences. Constructs encoding a direct fusion of NLS and GFP were digested with Agel, incubated with T4-polymerase in the presence of 4 dNTPs.
  • Linker insertion generated the following additional amino acid residues between NLS and the first copy of GFP: BamHI ala-asp- pro-pro (ADPP), EcoRI gly-asn-ser-pro (GNSP), Smal ala- pro-gly-pro (APGP).
  • ADPP BamHI ala-asp- pro-pro
  • GNSP EcoRI gly-asn-ser-pro
  • APGP Smal ala- pro-gly-pro
  • Protein SV40-GFP4 that contains the linker sequence ala-asp-pro-pro is referred to as SV40- ADPP-GFP4. All other constructs are named accordingly.
  • Plasmid p713 encodes GFP4 whose expression is controlled by five glucocorticoid response elements. To obtain this plasmid a KpnI/EcoRI fragment coding for the in frame fusion of four copies of GFP was inserted into the KpnI/EcoRI sites of
  • Plasmids to generate gene fusions containing GFP or NP- GFP To facilitate the generation of gene fusions containing different forms of GFP the following constructs were generated: Plasmid p827 was obtained by inserting a Xbal/PstI fragment encoding a mutant GFP (L64 T65) into the Xbal/PstI sites of pKS + . p657 is derived from p580; p580 was digested with BsmI and treated with T4-DNA-polymerase in the presence of 4 dNTPs. A Notl-linker (12mer, New England Biolabs) was ligated to the filled in DNA, followed by digestion with NotI and autoligation.
  • p657 is used to create fusion genes that encode GFP at their 5 '-end.
  • a derivative of p657 was generated by inserting the Ncol/Hpal fragment of p827 into p657 that was treated with Ncol and Hpal .
  • the resulting plasmid p833 contains GFP (L64 T65) carrying a Notl-linker at the former Bsml-site.
  • p834 was created by insertion of the
  • Plasmids encoding histidine-tagged versions of fluorescent marker proteins To generate genes encoding histidine-tagged marker proteins, coding sequences for the various fluorescent substrates were inserted in the appropriate pQE vector (Qiagen) to create in frame fusions of the histidine tag and the reporter protein. Specifically, to obtain His6-GFP4, plasmid p713 was digested with Agel and EcoRI, blunted and inserted into pQEll which was treated with BamHI and Klenow polymerase. These manipulations created plasmid p779 which encodes His6- GFP4 under control of the Escherichia coli tac pro- moter.
  • Plasmid p779 was digested with NotI, the 4.8kb fragment was autoligated resulting in plasmid p788 which encodes His6-GFP2. Treatment of plasmid p779 with Hpal and autoligation of the 4. lkb linearized band generated plasmid p790 which carries the coding sequence for His6-GFP1. To generate His6-NP-GFP4 , a Hindlll/EcoRI fragment containing the coding sequence for NP-GFP4 was blunted and cloned into pQElO treated with BamHI and Klenow-polymerase to remove recessive ends. Plasmid p778 codes for protein His6-NP-GFP4.
  • plasmid p791 which encodes His6- NP-GFP2.
  • Digestion of plasmid p778 with Hpal and autoligation of the 4. lkb band results in plasmid p792 which codes for His6-NP-GFP.
  • the respective pGRE5-2 vectors containing the constructs described were digested with EcoRI and Hindlll followed by treatment with T4 DNA-polymerase in the presence of 4 dNTPs.
  • GFP L64 T65 This mutant GFP-derivative GFPmutl, referred to as GFP L64 T65, was obtained from B. R. Cormack and published in 1996 ( Gene, 174:33-38).
  • nuclear substrates carrying the blue version of GFP are being created.
  • the blue version of GFP is mutant P4 obtained from Roger Tsien (Heim, R. et al . , 1994, Proc . Natl . Acad. Sci . , USA, 91:12501-12504). Plasmids for expression in Saccha.rom.yces cerevlslae
  • Genes encoding different nuclear substrates described in Table 1 are presently cloned into yeast expression vectors. The expression of gene fusions in these vectors is driven by the GAL1 control region. Gene expression is therefore induced when cells are grown on galactose as carbon source.
  • Fig. 1 Controls include proteins with one, two and four copies of GFP, which are termed GFP, GFP2 and GFP4, respectively. Fusion proteins were generated that carry the nucleoplasmin bipartite NLS (NP), the C- terminal half of nucleoplasmin (nucleoplasmin), SV40 wild type NLS (SV40), a mutant derivative (SV40*) and the inverse signal (SV40inv). Additional fusions were created that contain linker sequences between the NLS and the first copy of GFP. Only one construct harboring a linker sequence L and SV40-NLS is shown as an example. The different linker sequences inserted and fusion proteins containing these linkers are described below.
  • Control proteins include GFP and a fusion protein containing two and four copies of GFP, termed GFP2 and GFP4, respectively.
  • Polypeptide Nucleoplasmin- GFP contains the C-terminal half of Xenopus nucleoplasmin including the bipartite NLS and the DNA- binding region.
  • Proteins SV40-GFP4, SV40*-GFP4, SV40inv-GFP4 and NP-GFP4 carry wild type or mutant forms of the NLS at their N-termini as indicated. Derivatives of the proteins containing different linker sequences between NLS and GFP4 are described above.
  • the estimated molecular masses of GFP2 is about 60kD, for GFP4 and the NLS-containing derivatives approximately 120kD. When synthesized in E. coli and analyzed by denaturing gels, proteins migrate as expected.
  • HeLa cells were transiently transfected with plasmids that express fusion proteins under the control of an inducible promoter. Gene expression was induced by addition of dexamethasone to the growth medium. As shown in Fig. 2 for plasmids encoding NP-GFP and GFP, in the presence of dexamethasone cells exhibit bright fluorescence. HeLa cells were transiently transfected with plasmids encoding NP-GFP (panels A, B) or GFP (panels C, D) and gene expression was induced with dexamethasone as described herein.
  • NP-GFP is efficiently targeted to the nucleus due to the presence of the bipartite NLS derived from Xenopus nucleoplasmin.
  • non-transfected cells display only a low level of autofluorescence (Fig. 2).
  • Low autofluorescence signals were also obtained for non-induced cells, i.e., cells kept in the absence of dexamethasone.
  • linker insertion generated altered nuclear substrates that are recognized by the nuclear transport apparatus and targeted to the nucleus.
  • linker insertions were created for SV40*-GFP4 and SV40inv-GFP4, and we analyzed the cellular localization of the respective proteins (Fig. 5).
  • GFP4-derivatives containing the linker sequence ADPP (Panels A to F) or APGP (panels G to L) were transiently synthesized in HeLa cells.
  • Substrate proteins contained wild type SV40-NLS (panels A, B, G, H), mutant SV40*-NLS (panels C, D, I, J) or inverse SV40inv (panels E, F, K, L). Staining with DAPI (panels A, C, E, G, I, K) and green fluorescence (panels B, D, F, H, J, L) is shown.
  • Transport substrates carrying SV40inv-NLS were excluded from the nucleus (Fig. 5).
  • proteins containing the mutant SV40*-NLS were not excluded from nuclei.
  • these reporter proteins did not accumulate in nuclei.
  • NLS nuclear transport substrates containing four copies of GFP and different NLSs.
  • the type and context of the NLS specifies the localization of the reporter protein that can be easily followed in living cells. Diffusion from the nucleus into the cytoplasm
  • NP-GFP i.e., a fusion protein that contains the Xenopus nucleoplasmin NLS fused to one copy of GFP accumulated in nuclei under normal growth conditions
  • NP-GFP small size of approximately 30kD should permit NP-GFP to also traverse the nuclear pore complex by passive diffusion.
  • transiently transfected cells synthesizing NP-GFP showed bright nuclear fluorescence (Fig. 2).
  • the inducer dexamethasone was removed and cells were transferred to 4°C. Although this led to diffusion of NP-GFP from the nucleus into the cytoplasm, even after 4 hours of incubation at 4°C the nuclear fluorescence was more intense than the fluorescence signal seen for the cytoplasm.
  • NP-GFP sodium azide/2-deoxy D-glucose
  • azide/deoxyglucose sodium azide/2-deoxy D-glucose
  • Fig. 7 HeLa cells were incubated at room temperature with sodium azide/deoxyglucose and the nucleocytoplasmic distribution of the fluorescence signal was determined for 0 min, 10 min, 30 min, 45 min, 60 min and 90 min of the incubation with sodium azide/deoxyglucose as indicated in Fig. 7.
  • transiently transfected cells When induced with dexamethasone, transiently transfected cells show differences in the fluorescence which reflects different copy numbers of the plasmids introduced into each cell. In addition, transiently transfected cells loose the plasmid after prolonged culturing. Therefore, for many studies it is advantageous to have a uniform population of cells with comparable fluorescence. To this end, we created a stable cell line which carries the gene for nucleoplasmin-GFP. Cells were transfected and grown for two weeks without selection. Dexamethasone was added to the growth medium and cells displaying fluorescence were sorted by FACS . Under these conditions, approximately one in 10,000 cells gave a fluorescence signal. Single cells were isolated and further cultured.
  • NLS-GFP derivatives Different plasmid vectors encoding NLS-GFP derivatives will be useful to create fusion proteins that are targeted to the nucleus. If the protein of interest has deleterious effects, it is desirable to have an experimental system that permits the controlled induction of genes. To this end, promoters regulated by steroid hormone binding sites as described here for pGRE-derivatives will be optimal.
  • flanking sequences pro- vided by GFP could interfere with its function. It is currently believed that nuclear transport of proteins harboring SV40-NLS and the bipartite nucleoplasmin-NLS are both recognized by importin-alpha during nuclear transport. Since nucleoplasmin NLS directly fused to GFP or GFP4 was efficiently targeted to the nucleus, it is reasonable to assume that the N-terminal sequence of GFP does not inhibit binding to cytoplasmic NLS-recep- tors in general. We therefore favor the interpretation that SV40-NLS is not readily accessible for recognition by nuclear transport factors when directly fused to GFP4.
  • the small size of GFP permits this protein to enter the nucleus by passive diffusion. Fusion of the bipartite nucleoplasmin NLS to GFP efficiently mediated nuclear accumulation of the reporter protein.
  • the small size of NP-GFP i.e., approximately 30kD, made it an ideal tool to study diffusion from the nucleus into the cytoplasm.
  • NP-GFP exited the nucleus at low tempera- tures even in the absence of metabolic inhibitors.
  • Migration of NP-GFP into the cytoplasm of HeLa cells during chilling is not caused by irreversible damage of the cells or the nuclear envelope. HeLa cells survived this treatment, and the nuclear substrate was re- imported into nuclei after shifting to normal growth conditions.
  • the rapid nuclear exit of NP-GFP during chilling enables us to study diffusion in the absence of metabolic inhibitors which are likely to interfere with a variety of cellular processes.
  • NP- GFP will be useful as a tool to test how various drugs might interfere with diffusion across the nuclear envelope. The possible effect by these agents can be easily followed by fluorescence microscopy. Stable cell lines expression fluorescent reporter protein
  • NP-GFP or only GFP have also been generated, and we are currently creating additional cell lines which have improved fluorescence .
  • all of the cell lines described will allow the controlled expression not only of the fluorescent reporter protein but also of additional genes of interest. Since the cells contain the tTA-element (Damke, H. et al . , 1995, Meth . Enzym. , 257:209-220), they can be used to regulate the synthesis of a protein of interest by addition of tetracycline to the growth medium. Genes encoded on a tetracycline response plasmid are repressed in the presence of tetracycline, whereas in the absence of tetracycline gene expression is induced.
  • Nuclear substrates described in this study were also tested in other mammalian cell lines such as COS-7 and CHO cells. Similar results as described for HeLa cells were obtained, indicating that the reporter system we have developed is useful as a model to study nuclear transport in different mammalian cells. Taken together, we have established tools to study diffusion and signal-mediated transport across the nuclear envelope in higher eukaryotic cells. This sets the stage to analyze nucleocytoplasmic traffic in living mammalian cells in more detail.
  • Histidine-tagged (His6) versions of fluorescent reporter proteins have been created. Synthesis of these proteins is inducible in Escherichia coli . Fusion proteins are currently purified by affinity-purifica- tion and analyzed in in vi tro nuclear transport assays. The advantage of these substrates is that they are easy to purify in large quantities and at low costs. Previously used substrates for in vi tro studies involved the synthesis and covalent coupling of NLS- peptides, an expensive and laborious procedure.

Abstract

The present invention relates to reporter fusion proteins which allow the monitoring of facilitated transport and passive diffusion of proteins across the nuclear envelope in mammalian cells, cloning and expression vectors encoding these reporter proteins and transfected cell lines thereof. More particularly, the present invention relates to genes encoding reporter proteins to monitor transport and passive diffusion of proteins across the nuclear envelope in mammalian cells, which comprises a protein carrying a nuclear localization sequence (NLS) fused to at least one copy of a reporter protein, wherein the reporter protein allows for the visualization of the reporter fusion protein.

Description

REPORTER FUSION PROTEINS, EXPRESSION VECTORS AND TRANSFECTED CELL LINES THEREOF FOR THE ANALYSIS OF
NUCLEAR TRANSPORT
BACKGROUND OF THE INVENTION
(a) Field of the Invention
The invention relates to reporter fusion proteins which allow the monitoring of facilitated transport and passive diffusion of proteins across the nuclear envelope in mammalian cells, cloning and expression vectors encoding these reporter proteins and transfected cell lines thereof.
(b) Description of Prior Art
The correct localization of proteins in eukaryotes involves complex targeting reactions. These processes ensure that each cellular compartment contains an unique set of macromolecules required for the specialized function of the organelle. Proteins that are destined for the nucleus carry specific targeting sequences, termed nuclear .localization sequences (NLSs). The NLS is recognized by cytoplasmic NLS-recep- tors that dock at the nuclear pore complex which subsequently catalyzes the translocation across the nuclear envelope. Additional soluble factors are required for these transport reactions.
The nuclear pore complex mediates also diffusion, and proteins of molecular masses of 40kD or less can enter the nucleus via passive diffusion. By contrast, proteins that exceed the size of the diffu- sion channel enter the nucleus by a facilitated process that requires energy and a NLS. Polypeptides larger than 70kD are excluded from nuclei if they do not carry a functional NLS. NLSs can be divided into several classes. The NLS present in SV40 T-antigen is an exam- pie for a "simple" NLS containing a stretch of basic amino acid residues. A second class of NLSs contains "bipartite" sequences that carry two clusters of posi- tively charged amino acid residues that are separated by a spacer region, such as the NLS of Xenopus laevis nucleoplasmin. Another type of targeting sequences includes complex NLSs which do not fit into the classes of simple or bipartite signals.
So far, most experimental systems for the analysis of protein import in higher eukaryotes were based on in vitro reconstitution of transport or the injection of nuclear substrates into single cells. These experiments are tedious and time-consuming. A caveat of some of the reporter proteins used in these studies is their post-translational modification such as phospho- rylation which can modulate nuclear traffic.
It would be highly desirable to be provided with improved tools to monitor nuclear transport of proteins in vivo and in vi tro.
SUMMARY OF THE INVENTION
For the purpose of the present invention the following abbreviations are defined below.
ADPP ala-asp-pro-pro
APGP ala-pro-gly-pro
BSA bovine serum albumin
DAPI 4 ' , 6 ' -diamidino-2-phenylindole FACS Fluorescence activated cell sorting
GFP Aequorea victoria green fluorescent protein
GNSP gly-asn-ser-pro
NLS nuclear localization sequence NP-NLS NLS of Xenopus laevis nucleoplasmin
PBS phosphate buffered saline pKS+ plasmid pBluescript KS+
SV40-NLS NLS of SV40 T-antigen
SV40*-NLS mutant form of SV40-NLS SV40inv-NLS inverse sequence of SV40-NLS. To analyze nucleocytoplasmic traffic in growing cells, an experimental system which is based on the inducible synthesis of fluorescent reporter proteins was developed. Reporter proteins of various sizes described here carry different NLSs which are fused to the Aequorea victoria green fluorescent protein (GFP). These substrates were expressed and localized in mammalian culture cells. In addition to the analysis of facilitated protein transport into nuclei, assays to study passive diffusion from the nucleus into the cytoplasm were described. To facilitate the generation of gene fusions that encode different mutants of GFP with or without a nuclear localization sequence several new cloning vectors were generated. Moreover, in accordance with the present invention, a stable cell line that produces a nuclear reporter protein under control of an inducible promoter was analyzed. Upon induction, single cells of this clone synthesize similar amounts of the reporter pro- tein. In accordance with the present invention, such cell lines offer the advantage that large numbers of cells can be tested simultaneously under identical conditions. Additional stable cell lines are currently generated for more detailed analyses of transport and diffusion across the nuclear envelope. Taken together, novel experimental tools to investigate nucleocytoplasmic transport and diffusion in intact mammalian cells were described.
In addition to the analysis of nuclear traffic in growing cells, tagged nuclear transport substrates carrying various numbers of GFP to study nucleocytoplasmic traffic in vi tro were also generated. These substrates can be expressed in Escherichia coli and purified by metal affinity-chromatography . The purified substrates are currently tested with semi-permeabilized HeLa cells and with yeast spheroplasts to demonstrate that these proteins are bona fide substrates for nuclear transport.
In accordance with the present invention there is provided genes encoding reporter proteins to monitor transport and passive diffusion of proteins across the nuclear envelope in mammalian cells, which comprises a protein carrying a nuclear localization sequence (NLS) fused to at least one copy of a reporter protein, wherein the reporter protein allows for the visualization of the reporter fusion protein.
In accordance with one embodiment of the present invention, the NLS derived from SV40 T-antigen is connected to the reporter protein via a linker sequence encoding small amino acid residues. The NLS may also be derived from Xenopus laevis nucleoplasmin or present in the C-terminal portion of nucleoplasmin.
In accordance with one embodiment of the present invention, there is provided an expression vector to transiently and stably express reporter genes of the present invention, which comprises a gene encoding a protein carrying a nuclear localization sequence (NLS) fused to at least one copy of a reporter protein, wherein expression of the gene is under the control of an inducible promoter.
The NLS may be connected to the reporter protein via a linker sequence encoding small amino acid residues.
In accordance with another embodiment of the present invention, the reporter protein may be any fluorescent protein such as Aequorea vi ctoria green fluorescent protein (GFP).
In accordance with one embodiment of the present invention, there is provided, a cell line stably expressing a nuclear reporter protein to monitor trans- port and passive diffusion of proteins across the nuclear envelope, which comprises a cell line trans- fected by the expression vector of the present invention. The NLS may be fused to the reporter protein by a linker encoding small amino acid residue.
The cell lines may be selected from the group consisting of HeLa, COS and CHO.
In accordance with another embodiment of the present invention, there is provided an in vivo assay for screening compounds which affect transport and/or passive diffusion of proteins across the nuclear envelope in mammalian cells, which comprises the steps of: a) treating a stably transfected cell line of the present invention with a compound; and b) visualizing the distribution of reporter protein in nuclei and cytoplasm.
In accordance with another embodiment of the present invention, there is provided an in vi tro assay for screening compounds which affect transport and/or passive diffusion of proteins across the nuclear envelope in mammalian cells, which comprises the steps of: a) treating semi-permeabilized cells which support in vitro nuclear transport with a compound and a pro- tein of the present invention; and b) visualizing the distribution of reporter protein in nuclei and cytoplasm.
In accordance with one embodiment of the present invention, the cells may be treated with the compound and protein concurrently or one after the other.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 illustrates a schematic representation of different fluorescent reporter proteins containing GFP used in this study; Fig. 2 illustrates transient expression of fusion proteins harboring one copy of GFP;
Fig. 3 illustrates transient expression of transport substrates with two and four copies of GFP; Fig. 4 illustrates the effect of linker sequences on the localization of SV40-GFP4;
Fig. 5 illustrates the localization of reporter proteins harboring wild type and mutant versions of SV40-NLS; Figs. 6A and 6B illustrate nucleocytoplasmic diffusion of NP-GFP, (A) chilling of cells, (B) treatment with sodium azide/deoxyglucose at different temperatures ;
Fig. 7 illustrates the kinetics of the diffusion of NP-GFP across the nuclear envelope in HeLa cells treated with sodium azide/deoxyglucose; and
Fig. 8 illustrates stably transfected HeLa cells expressing nucleoplasmin-GFP.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided an experimental system to study nucleocytoplasmic traffic of proteins in living mammalian cells. Towards this goal, substrates were generated that contain one or more copies of Aequorea victoria green fluorescent protein (GFP). Reporter proteins of various sizes that carry different nuclear localization sequences (NLSs) were created to follow facilitated transport and passive diffusion across the nuclear envelope. The expression of reporter genes was controlled by an inducible promoter. Transiently and stably transfected HeLa cells were employed to follow the sorting of fluorescent reporter proteins. When NLS-GFP fusions were located in HeLa cells it was found that direct fusion of the NLS derived from SV40 T-anti- gen to GFP prevented nuclear accumulation of the protein. However, insertion between NLS and GFP of different linkers encoding small amino acid residues produced reporter proteins that were competent for nuclear import.
Furthermore, it is demonstrated in accordance with the present invention that a small protein of approximately 30kD that harbors one copy of GFP and the bipartite Xenopus nucleoplasmin NLS accumulates effi- ciently in nuclei of HeLa cells. Under conditions which abolish active facilitated nuclear transport the protein diffuses across the nuclear envelope. This polypeptide can therefore be used as a reporter to analyze passive diffusion between nucleus and cyto- plasm.
In addition to transient expression of novel transport substrates, stable cell lines that carry different genes for a fluorescent nuclear reporter protein were created. These cell lines provide an unique and novel tool for the characterization of nuclear protein import and diffusion in dividing human cells .
Based on the substrates to study nuclear traffic in growing cells of the present invention, histidine tagged versions of reporter proteins which permits their purification by metal affinity chromatography were also generated.
EXPERIMENTAL PROCEDURES Cell culture and transfection
HtTA-1 cells are described in detail in Damke et al., 1995 (Damke, H. et al . , 1995, Meth . Enzym. ,
257:209-220). HtTA-1 cells contain the tTA-element which permits the control of gene expression by addi- tion of tetracycline to the growth medium. HeLa cells were grown in Dulbecco's modified essential medium (DMEM) containing penicillin G (50U/ml), streptomycin (50μg/ml) and 8 % fetal bovine serum (complete medium). Cultures were maintained at 37°C in a humidified atmosphere containing 5% Cθ2 • For transient transfections cells were subcultured on six- well tissue culture plates and DNA was introduced with the calcium phosphate/DNA coprecipitation method and CalPhos Maximizer™ (Bio/Can, Mississauga, Ontario) or by use of the DOSPER™ Liposomal Transfection Reagent (Boehringer Mannheim, Canada) according to the manufacturer's instructions. Approximately 16 hrs to 24 hrs after addition of DNA, medium was removed and HeLa cells were kept in complete medium containing 50 nM dexamethasone. To generate stable cell lines, HtTA-1 cells were transfected following the modified transfection protocol described (Sambrook, J., Fritsch, E.F. and Maniatis, T., 1989, in Molecular Cloning, 2nd ed. , pp 16.33-16.36, Cold Spring Harbor Laboratory Press).
Detection of transiently transfected cells expressing GFP-derivatives
Cells were incubated overnight with DNA followed by addition of fresh medium. Approximately 7 hours after the change of medium, cells were harvested by trypsinization and transferred to LabTek tissue culture chamber slides (Gibco, BRL). HeLa cells were kept for another 16 to 44 hours in complete medium containing 50 nM dexamethasone. To study diffusion, cells were washed with medium lacking dexamethasone and incubated in dex- amethasone-free medium for 1 hour at 37°C prior to analysis of diffusion. To follow diffusion of nuclear substrates across the nuclear envelope, cells were washed with PBS and incubated in PBS in the cold. Alternatively, cells were treated with 10 mM sodium azide and 10 mM 2-deoxy D-glucose in PBS as described for Figs. 6 and 7.
All subsequent steps were carried out at room temperature. For fixation slides were washed twice in phosphate buffered saline (PBS), incubated for 25 min in PBS/3.7% formaldehyde and washed three times with PBS. Samples were incubated with PBS containing ',6'- Diamidino-2-phenylindole (DAPI) and 2 mg/ml bovine serum albumin (BSA), and washed twice in PBS. Slides were mounted in 30% glycerol in PBS. Slides were sealed with rubber cement and kept at 4°C. The fluorescence signals were stable for several weeks.
Generation of stable cell lines and detection of nuclear reporter proteins
HtTA-1 cells were grown and transfected as described above. Transfected cells were grown under standard conditions for at least two weeks without selection. One day after addition of 50 nM dexametha- sone, cells were sorted by FACS into 24-well plates under sterile conditions . A maximum of one cell per well was obtained after sorting. Cells were further grown for two to three weeks and analyzed for the synthesis of nuclear reporter proteins. Towards this end, stable cell lines were kept in the presence of 50 nM dexamethasone ( 2 days ) and analyzed by fluorescence microscopy as described above. Plasmid constructions
Plasmid pGRE5-2, was used as a vector for genes encoding different fluorescent substrates. Gene expression is controlled by glucocorticoid response elements and can be induced by dexamethasone (Mader, S and White, J., 1993, Proc . Na tl . Acad. Sci USA, 90:5603- 5607). A mutant version of GFP in pBluescriptKS"1" carry- ing a Ser65 —> Thr65 substitution by PCR-amplification of the GFP-DNA using appropriate primers was generated. This created plasmid p580 which contains the mutant GFP allele cloned into the KpnI/EcoRI sites of pBluescript
KS+ ( Chatterjee, S. and Stochaj , U., 1996,
BioTechniques, 21:62-63).
Plasmids encoding nuclear substrates with one or two copies of GFP
The generation of the gene encoding Nucleoplas- min-GFP, i.e., the C-terminal half of Xenopus nucleo- plasmin fused to a single copy of GFP has been described (Chatterjee, S. and Stochaj , U., 1996, BioTechniques, 21: 62-63). A gene fusion encoding nucleoplasmin NLS and GFP, termed NP-GFP, was created by fusion of oligonucleotides encoding the NLS (Barth, W. and Stochaj , U., 1996, Biochem. Cell Biol . , 74: 363- 372) to GFP. Plasmid p709 is derived from pGRE5-2 and codes for NP-GFP. Gene fusions containing two copies of GFP were created by removal of the UAG stop codon of GFP followed by insertion of a NotI linker (12mer, New England Biolabs). In addition, a Notl-linker was inserted into the KpnI-site of plasmid p580. Both copies of the GFP coding sequence were fused in frame via their Notl-sites thereby creating GFP2 in pBluescript (plasmid p690). Insertion of the KpnI/EcoRI fragment of p690 into the KpnI/EcoRI sites of pGRE5-2 created plasmid p785. For p785, the expression of GFP2 is driven by an inducible promoter carrying 5 glucocor- ticoid response elements. Plasmids encoding fusion proteins containing four copies of GFP
DNAs encoding different NLSs were cloned into pGRE5-2. These vectors were digested with Xhol and
EcoRI and a 2.8 kb XhoI/EcoRI fragment encoding four copies of GFP was ligated into the vector DNA.
Following this ligation, DNA was digested with Xhol and
Agel. Recessed ends were filled in and DNA was autoli- gated. The resulting plasmids p732, p733, p734 and p767 encode fusion proteins NP-GFP4, SV40-GFP4, SV40*-GFP4, and SV40inv-GFP4, respectively (Fig. 1). Derivatives of plasmids carrying wild type or mutant versions of SV40- NLS fused to GFP4 were generated by in frame insertion of linker sequences. Constructs encoding a direct fusion of NLS and GFP were digested with Agel, incubated with T4-polymerase in the presence of 4 dNTPs. 8mer linkers (New England Biolabs) carrying a BamHI, EcoRI or Smal-site were inserted. Linker insertion generated the following additional amino acid residues between NLS and the first copy of GFP: BamHI ala-asp- pro-pro (ADPP), EcoRI gly-asn-ser-pro (GNSP), Smal ala- pro-gly-pro (APGP). Protein SV40-GFP4 that contains the linker sequence ala-asp-pro-pro is referred to as SV40- ADPP-GFP4. All other constructs are named accordingly. Plasmid p713 encodes GFP4 whose expression is controlled by five glucocorticoid response elements. To obtain this plasmid a KpnI/EcoRI fragment coding for the in frame fusion of four copies of GFP was inserted into the KpnI/EcoRI sites of pGRE5-2.
Plasmids to generate gene fusions containing GFP or NP- GFP To facilitate the generation of gene fusions containing different forms of GFP the following constructs were generated: Plasmid p827 was obtained by inserting a Xbal/PstI fragment encoding a mutant GFP (L64 T65) into the Xbal/PstI sites of pKS+. p657 is derived from p580; p580 was digested with BsmI and treated with T4-DNA-polymerase in the presence of 4 dNTPs. A Notl-linker (12mer, New England Biolabs) was ligated to the filled in DNA, followed by digestion with NotI and autoligation. p657 is used to create fusion genes that encode GFP at their 5 '-end. A derivative of p657 was generated by inserting the Ncol/Hpal fragment of p827 into p657 that was treated with Ncol and Hpal . The resulting plasmid p833 contains GFP (L64 T65) carrying a Notl-linker at the former Bsml-site. Similarly, p834 was created by insertion of the
Ncol/Hpal fragment of p827 into plasmid p580.
Plasmids encoding histidine-tagged versions of fluorescent marker proteins To generate genes encoding histidine-tagged marker proteins, coding sequences for the various fluorescent substrates were inserted in the appropriate pQE vector (Qiagen) to create in frame fusions of the histidine tag and the reporter protein. Specifically, to obtain His6-GFP4, plasmid p713 was digested with Agel and EcoRI, blunted and inserted into pQEll which was treated with BamHI and Klenow polymerase. These manipulations created plasmid p779 which encodes His6- GFP4 under control of the Escherichia coli tac pro- moter. Plasmid p779 was digested with NotI, the 4.8kb fragment was autoligated resulting in plasmid p788 which encodes His6-GFP2. Treatment of plasmid p779 with Hpal and autoligation of the 4. lkb linearized band generated plasmid p790 which carries the coding sequence for His6-GFP1. To generate His6-NP-GFP4 , a Hindlll/EcoRI fragment containing the coding sequence for NP-GFP4 was blunted and cloned into pQElO treated with BamHI and Klenow-polymerase to remove recessive ends. Plasmid p778 codes for protein His6-NP-GFP4. Treatment of p778 with NotI and autoligation of the 4.8kb band generated plasmid p791 which encodes His6- NP-GFP2. Digestion of plasmid p778 with Hpal and autoligation of the 4. lkb band results in plasmid p792 which codes for His6-NP-GFP. To create histidine-tagged versions of GFP4 derivatives carrying different SV40- NLSs, the respective pGRE5-2 vectors containing the constructs described were digested with EcoRI and Hindlll followed by treatment with T4 DNA-polymerase in the presence of 4 dNTPs. Purified 2.8kb fragments were inserted in pQElO which had been treated with BamHI and T4 DNA-polymerase plus 4 dNTPs. Plasmids p778, p791, p792, p799, p788, p790, p818, p819, p824, p828, p829 and p830 and the different NLSs they encode are listed in Table 1.
The different sequences listed in Table 1 are described in Barth and Stochaj , 1996 (Barth, W. and Stochaj, U., 1996, Biochem. Cell Biol . , 74:363-372). Inserted linker sequences BamHI, EcoRI and Smal are shown in italics (Table 1). Plasmids p827, p833 and p834 carry a mutant GFP (F64L S65T) as described by Cormack et al . , 1996 (Cormack, B.P. et al . , 1996, Gene, 174: 33-38). The backbones of the plasmids and the respective fusion genes are listed in Table 1. In addition, it is stated which organisms can be used for the inducible expression of gene fusions.
Table 1
Generation of different plasmids to analyze nuclear transport of proteins and diffusion across the nuclear envelope
Plasmid name Backbone Gene encoded Inducible expression in p580 pBluescript KS+ GFP —
P585 PGRE5-2 Nucleoplasmin-GFP mammalian cells p657 pBluescript KS+ GFP carrying a Notl- — linker at 3'-end p827 pBluescript KS+ GFP L64 T65 — p833 pBluescript KS+ same as p657 but GFP — L64 T65 p834 pBluescript KS+ same as p657 but GFP — L64 T65
P709 PGRE5-2 NP-GFP mammalian cells p775 pBluescript KS+ NP-GFP — p776 pBluescript KS+ NP-GFP (blue GFP) — p777 PGRE5-2 NP-GFP (blue GFP) mammalian cells p732 pGRE5-2 NP-GFP4 mammalian cells p733 PGRE5-2 SV40-GFP4 mammalian cells p734 pGRE5-2 SV40*-GFP4 mammalian cells p767 pGRE5-2 SV40inv-GFP4 mammalian cells p764 pGRE5-2 SV40-Sma/-GFP4 mammalian cells p765 pGREδ-22 SV40-EcoR/-GFP4 mammalian cells p795 pGRE5-2 SV40-BamH/-GFP4 mammalian cells p780 pGRE5-2 SV40inv-Ba nH/-GFP4 mammalian cells p781 pGREδ-2 SV40*-SamH/-GFP4 mammalian cells p782 pGREδ-2 SV40inv-Sma/-GFP4 mammalian cells p783 pGRE5-2 SV40*-Sma/-GFP4 mammalian cells p784 pGRE5-2 SV40inv-EcoR/-GFP4 mammalian cells p785 pGRE5-2 GFP2 mammalian cells p778 pQE His6-NP-GFP4 Escherichia coli p791 pQE His6-NP-GFP2 Escherichia coli p792 pQE His6-NP-GFP Escherichia coli p779 pQE His6-GFP4 Escherichia coli p788 pQE His6-GFP2 Escherichia coli p790 pQE His6-GFP Escherichia coli p818 pQE His6-SV40-SamH/- Escherichia coli GFP4 p819 pQE His6-SV40inv-Baπ?H/- Escherichia coli GFP4 p824 pQE His6-SV40*-Sa/rjf /- Escherichia coli GFP4 p828 pQE His6-SV40-Sma/-GFP4 Escherichia coli p829 pQE His6-SV40*-Sma/- Escherichia coli GFP4 p830 pQE His6-SV40inv-Sma/- Escherichia coli GFP4
Plasmids encoding different mutants of GFP
In accordance with the present invention, additional plasmids which are identical to those listed in Table 1 but carry a different version of GFP are currently being generated. GFP used to generate these plasmids carries a mutation at position at amino acid residue 64. The wild type Phe64 was replaced by Leu64 (F64L). This mutant GFP-derivative GFPmutl, referred to as GFP L64 T65, was obtained from B. R. Cormack and published in 1996 ( Gene, 174:33-38). In addition, nuclear substrates carrying the blue version of GFP are being created. The blue version of GFP is mutant P4 obtained from Roger Tsien (Heim, R. et al . , 1994, Proc . Natl . Acad. Sci . , USA, 91:12501-12504). Plasmids for expression in Saccha.rom.yces cerevlslae
Genes encoding different nuclear substrates described in Table 1 are presently cloned into yeast expression vectors. The expression of gene fusions in these vectors is driven by the GAL1 control region. Gene expression is therefore induced when cells are grown on galactose as carbon source.
USE OF THE INVENTION
Generation of nuclear substrates containing GFP
Different genes encoding fusion proteins that are substrates for nuclear transport were created. The various constructs used in our studies are depicted in Fig. 1. Controls include proteins with one, two and four copies of GFP, which are termed GFP, GFP2 and GFP4, respectively. Fusion proteins were generated that carry the nucleoplasmin bipartite NLS (NP), the C- terminal half of nucleoplasmin (nucleoplasmin), SV40 wild type NLS (SV40), a mutant derivative (SV40*) and the inverse signal (SV40inv). Additional fusions were created that contain linker sequences between the NLS and the first copy of GFP. Only one construct harboring a linker sequence L and SV40-NLS is shown as an example. The different linker sequences inserted and fusion proteins containing these linkers are described below.
Control proteins include GFP and a fusion protein containing two and four copies of GFP, termed GFP2 and GFP4, respectively. Polypeptide Nucleoplasmin- GFP contains the C-terminal half of Xenopus nucleoplasmin including the bipartite NLS and the DNA- binding region. Proteins SV40-GFP4, SV40*-GFP4, SV40inv-GFP4 and NP-GFP4 carry wild type or mutant forms of the NLS at their N-termini as indicated. Derivatives of the proteins containing different linker sequences between NLS and GFP4 are described above. The estimated molecular masses of GFP2 is about 60kD, for GFP4 and the NLS-containing derivatives approximately 120kD. When synthesized in E. coli and analyzed by denaturing gels, proteins migrate as expected.
Transient expression of GFP-containing transport substrates in HeLa cells To determine the cellular localization of transport substrates, HeLa cells were transiently transfected with plasmids that express fusion proteins under the control of an inducible promoter. Gene expression was induced by addition of dexamethasone to the growth medium. As shown in Fig. 2 for plasmids encoding NP-GFP and GFP, in the presence of dexamethasone cells exhibit bright fluorescence. HeLa cells were transiently transfected with plasmids encoding NP-GFP (panels A, B) or GFP (panels C, D) and gene expression was induced with dexamethasone as described herein. DAPI-staining of the DNA (panels A, C) and green fluorescence (panels B, D) is shown. NP-GFP is efficiently targeted to the nucleus due to the presence of the bipartite NLS derived from Xenopus nucleoplasmin. By contrast, non-transfected cells display only a low level of autofluorescence (Fig. 2). Low autofluorescence signals were also obtained for non-induced cells, i.e., cells kept in the absence of dexamethasone.
When GFP lacking a NLS was synthesized in HeLa cells, GFP was detected in both the cytoplasm and the nucleus (Fig. 2). This distribution is expected, since the small size of the protein permits its translocation across the nuclear envelope by passive diffusion. We also expressed a gene encoding two copies of GFP (GFP2) in HeLa cells. GFP2, a protein with a molecular mass of approximately 60kD was also found to traverse the nuclear envelope (Fig. 3). HeLa cells synthesizing GFP2 (panels A, B), GFP4 (panels C, D) and NP-GFP4 (panels E, F) were transiently transfected and processed in accordance with the present invention. DAPI-staining (panels A, C, E) and green fluorescence (panels B, D, F) are illustrated. The amount of GFP2 in nuclei, however, was relatively low, most likely the larger molecular mass restricted its diffusion across the nuclear pore. The nuclear pore mediates transport of macro- molecules across the nuclear envelope and molecules with a molecular mass of more than 70kD are excluded from the nucleus unless they carry a NLS. To obtain reporter proteins that exceed the size for passive diffusion, we have generated substrates that contain four copies of GFP. As shown in Fig. 3, in transiently transfected cells GFP4 was restricted to the cytoplasm and could not be detected in nuclei (panels C, D). On the basis of these results we created several different reporter proteins that contain four copies of GFP in addition to wild type or mutant forms of NLSs (Fig. 1).
Our initial experiments included the generation of constructs for which the NLS was directly fused to the first copy of GFP. For the bipartite nucleoplasmin- NLS, i.e., NP-GFP4, efficient import into nuclei was obtained (Fig. 3, panels E, F). By contrast, constructs containing wild type SV40-NLS fused to GFP4 did not accumulate in nuclei (Fig. 4, panels A and B) . Similarly, reporter proteins containing mutant versions of SV40-NLS fused to GFP4 were excluded from nuclei. It has previously been reported for SV40-NLS and other NLSs that flanking protein sequences, i.e., context of the NLS can affect the efficiency of nuclear targeting. We therefore reasoned that addition of amino acid resi- dues between SV40-NLS and GFP4 could improve nuclear targeting of the fusion protein. Different linker sequences encoding short stretches of amino acid residues were inserted between SV40-NLS and GFP4. Linker sequences coded for proline and amino acid residues with small side chains that have the potential to form β-turns. Residues with small side chains are expected to provide flexibility of the linker. The linkers used generated the following extra amino acid sequences (one letter code) BamHI - ADPP, EcoRI - GNSP and Smal-APGP. Reporter proteins containing wild type SV40-NLS and one of the different linker sequences were found to accumulate in nuclei (Fig. 4, panels C-H). Fusion proteins SV40-GFP4 containing SV40-NLS directly fused to GFP (panel A, B), or connected by different linker sequences were localized. Insertion of the peptide sequence ADPP (panels C, D), GNSP (panels E, F) and APGP (panels G, H) resulted in nuclear localization of reporter proteins. DAPI staining (panels A, C, E, G) and green fluorescence (panels B, D, F, H) were analyzed in parallel.
This demonstrates that linker insertion generated altered nuclear substrates that are recognized by the nuclear transport apparatus and targeted to the nucleus. We concentrated on constructs containing link- ers ADPP or APGP for further studies. Towards this end, linker insertions were created for SV40*-GFP4 and SV40inv-GFP4, and we analyzed the cellular localization of the respective proteins (Fig. 5). GFP4-derivatives containing the linker sequence ADPP (Panels A to F) or APGP (panels G to L) were transiently synthesized in HeLa cells. Substrate proteins contained wild type SV40-NLS (panels A, B, G, H), mutant SV40*-NLS (panels C, D, I, J) or inverse SV40inv (panels E, F, K, L). Staining with DAPI (panels A, C, E, G, I, K) and green fluorescence (panels B, D, F, H, J, L) is shown.
Transport substrates carrying SV40inv-NLS were excluded from the nucleus (Fig. 5). By contrast, proteins containing the mutant SV40*-NLS were not excluded from nuclei. However, these reporter proteins did not accumulate in nuclei. These results are consistent with previously published data that show nuclear targeting via this mutant NLS albeit with reduced efficiency.
Taken together, we have generated several nuclear transport substrates containing four copies of GFP and different NLSs. The type and context of the NLS specifies the localization of the reporter protein that can be easily followed in living cells. Diffusion from the nucleus into the cytoplasm
In order to study diffusion of a polypeptide across the nuclear envelope, a reporter protein is required that is small enough to traverse the nuclear pore in the absence of nuclear import or export signals. NP-GFP, i.e., a fusion protein that contains the Xenopus nucleoplasmin NLS fused to one copy of GFP accumulated in nuclei under normal growth conditions
(Fig. 2). However, the small size of approximately 30kD should permit NP-GFP to also traverse the nuclear pore complex by passive diffusion. As described above, transiently transfected cells synthesizing NP-GFP showed bright nuclear fluorescence (Fig. 2). To test whether this protein can diffuse across the nuclear envelope, the inducer dexamethasone was removed and cells were transferred to 4°C. Although this led to diffusion of NP-GFP from the nucleus into the cytoplasm, even after 4 hours of incubation at 4°C the nuclear fluorescence was more intense than the fluorescence signal seen for the cytoplasm. If cells were incubated for 4 hours at 4 °C and returned to 37°C in growth medium cytoplasmic NP- GFP was re-imported into nuclei demonstrating that active facilitated transport was regained under normal growth conditions. Prolonged incubation at 4°C resulted in rounding of HeLa cells which was also reversible. Round cells flattened again and spread on the slide after overnight incubation at 37°C. A more pronounced exit of NP-GFP from the nucleus into the cytoplasm was obtained when cells were incubated 2 hours at 4°C and subsequently kept for 2 hours on ice. Under these conditions fluorescence signals observed for nuclei and for the cytoplasm were of similar intensity, indicating the efficient equilibration of NP-GFP between nucleus and cytoplasm (Fig. 6A) . HeLa cells transiently expressing the NP-GFP gene were incubated for 2 hours at 4°C, followed by 2 hours on ice. The distribution of fluorescence was determined before (panels A, B) and after chilling (panels C, D). After incubation on ice cells were returned to 37°C and incubated overnight in the absence of the inducer dexamethasone to test for re-import of NP-GFP into the nucleus (panels E, F) . Panels A, C, D show phase contrast, panels B, D and F the distribution of fluorescence.
These results support the idea that in chilled HeLa cells NP-GFP left the nucleus by diffusion and nuclear accumulation of NP-GFP is prevented due to the absence of active facilitated transport into the nucleus. To determine whether nuclear exit of NP-GFP is reversible, cells were first treated 2 hours at 4°C and 2 hours on ice and subsequently incubated in growth medium at 37°C (Fig. 6A) . Under these conditions cyto- plasmic NP-GFP was re-imported into nuclei demonstrating that diffusion across the nuclear envelope was reversible and cells recovered from chilling.
In addition to cold treatment, we also tested the effect of sodium azide/2-deoxy D-glucose (azide/deoxyglucose) on the localization of NP-GFP. After incubation of transiently transfected cells with azide/deoxyglucose, NP-GFP equilibrated efficiently between nucleus and cytoplasm (Fig. 6B). Transiently transfected HeLa cells containing NP-GFP were incubated with azide/deoxyglucose as described herein. The localization of NP-GFP was determined before (panels A, B and G, H) and after treatment with sodium azide/deoxyglucose for 45 min (panels C, D and I, J). Slides were washed in PBS and incubated overnight with medium lacking dexamethasone to analyze accumulation of NP-GFP in the nucleus (panels E, F and K, L). Identical experiments were carried out on ice (panels A - F) and at room temperature (panels G - L). Phase contrast is presented in panels A, C, E, G, I, K, the location of fluorescent proteins is shown in panels B, D, F, H, J and L.
We further determined whether incubation with azide/deoxyglucose led to nuclear exit of NP-GFP at other temperatures. As demonstrated in Fig. 6B treat- ment at room temperature or at 37°C results in diffusion of NP-GFP across the nuclear envelope. For all the different temperatures tested, we found that upon return of cells to normal growth medium and 37°C, reimport of NP-GFP was observed for at least a fraction of cells. After incubation with azide/deoxyglucose at 37°C fewer cells seemed to recover when compared to those treated at room temperature or incubated on ice.
To study diffusion of NP-GFP across the nuclear envelope in more detail, we followed the distribution of fluorescence in cells that were incubated with azide/deoxyglucose at room temperature (Fig. 7). HeLa cells were incubated at room temperature with sodium azide/deoxyglucose and the nucleocytoplasmic distribution of the fluorescence signal was determined for 0 min, 10 min, 30 min, 45 min, 60 min and 90 min of the incubation with sodium azide/deoxyglucose as indicated in Fig. 7.
A gradual increase of cytoplasmic fluorescence was seen upon treatment with azide/deoxyglucose. The equilibration of NP-GFP was complete at approximately 45 min, and prolonged incubations with inhibitors did not lead to further changes .
Generation and characterization of a stable cell line expressing Nucleoplasmin-GFP
When induced with dexamethasone, transiently transfected cells show differences in the fluorescence which reflects different copy numbers of the plasmids introduced into each cell. In addition, transiently transfected cells loose the plasmid after prolonged culturing. Therefore, for many studies it is advantageous to have a uniform population of cells with comparable fluorescence. To this end, we created a stable cell line which carries the gene for nucleoplasmin-GFP. Cells were transfected and grown for two weeks without selection. Dexamethasone was added to the growth medium and cells displaying fluorescence were sorted by FACS . Under these conditions, approximately one in 10,000 cells gave a fluorescence signal. Single cells were isolated and further cultured. Characterization of stable transfectants demonstrated that the fluorescence signal observed varied between different clones. This most likely reflects variable levels of gene expression due to differences in the integration sites of the plasmid. However, fluorescence signals for single cells derived from the same clone were comparable (Fig. 8, panels C, D). HeLa cells were transfected with a plasmid encoding Nucleoplasmin-GFP and stable transfectants were selected as described herein. Green fluorescence obtained after induction of gene expression with dexamethasone (panel B) or in the absence of dexamethasone (panel D) was determined. Nuclei were detected by staining with DAPI (panel A, C).
In the absence of the inducer dexamethasone, no fluorescence signal was obtained demonstrating the tight control of gene expression in this experimental system (Fig. 8) .
Additional stable cell lines have been generated that express NP-GFP and GFP only. We are presently creating a larger number of these stable cell lines to obtain clones with improved fluorescence.
Previous and future use of plasmids and cell lines
We have generated a nuclear transport system that permits the analysis of nuclear import and passive diffusion of proteins from the nucleus into the cytoplasm. To achieve this goal, we have created a variety of fusion proteins that contain one, two or four copies of GFP. Generation of fusion proteins containing GFP and a nuclear localization signal
Different plasmid vectors encoding NLS-GFP derivatives will be useful to create fusion proteins that are targeted to the nucleus. If the protein of interest has deleterious effects, it is desirable to have an experimental system that permits the controlled induction of genes. To this end, promoters regulated by steroid hormone binding sites as described here for pGRE-derivatives will be optimal.
Analysis of nuclear transport in mammalian cell lines Analysis of facilitated transport in HeLa cells requires substrates that are unable to enter the nucleus by diffusion. Therefore, we have designed fusion proteins whose size prevents them from diffusing across the nuclear pore. These nuclear substrates contain four copies of GFP, and in the absence of a functional NLS GFP4 was excluded from nuclei. By contrast, protein GFP2 which contains two copies of GFP was present in nuclei, indicating that GFP2 could diffuse across the nuclear envelope. The translocation of GFP2 into nuclei is not mediated by a cryptic NLS since such a signal would also be present in GFP4, a protein we have shown to be excluded from nuclei. Thus, although the molecular mass of GFP2 is close to the exclusion size of nuclear pores for passive diffusion, it can still traverse the nuclear envelope of HeLa cells .
Since GFP4 remained cytoplasmic in HeLa cells, we concentrated on the generation of reporter proteins that harbor four copies of GFP. Nucleoplasmin NLS pro- vided a functional signal when directly fused to the GFP4-moiety, demonstrating that the context provided by GFP4 permits the recognition of the bipartite signal and nuclear accumulation of NP-GFP4. In contrast to nuclear targeting via nucleoplasmin NLS, direct fusion of SV40-NLS to GFP4 did not result in nuclear targeting of the fusion protein. These results can be interpreted as the failure of cytoplasmic factors to bind the simple SV40-NLS when fused to GFP4 due to steric hindrance. Alternatively, the flanking sequences pro- vided by GFP could interfere with its function. It is currently believed that nuclear transport of proteins harboring SV40-NLS and the bipartite nucleoplasmin-NLS are both recognized by importin-alpha during nuclear transport. Since nucleoplasmin NLS directly fused to GFP or GFP4 was efficiently targeted to the nucleus, it is reasonable to assume that the N-terminal sequence of GFP does not inhibit binding to cytoplasmic NLS-recep- tors in general. We therefore favor the interpretation that SV40-NLS is not readily accessible for recognition by nuclear transport factors when directly fused to GFP4. Introduction of linker sequences that encode a stretch of small amino acid residues, however, enabled SV40-NLS to target GFP4 to the nucleus. Control experiments were carried out with fusion proteins containing identical linker insertions and SV40*-NLS or SV40inv- NLS. SV40*-GFP4 did not accumulate and SV40inv-GFP4 was excluded from nuclei demonstrating that the inserted linker sequence does not function as a cryptic NLS. When compared to GFP4 or SV40inv-GFP carrying different linker insertions it was observed that SV40*-GFP was not excluded from nuclei. This result is in agreement with previous studies which showed that the mutant NLS of SV40-T antigen harboring a Lysl28->Thrl28 mutation can still function as a weak NLS.
Analysis of diffusion across the nuclear envelope
As previously described by us the small size of GFP permits this protein to enter the nucleus by passive diffusion. Fusion of the bipartite nucleoplasmin NLS to GFP efficiently mediated nuclear accumulation of the reporter protein. The small size of NP-GFP, i.e., approximately 30kD, made it an ideal tool to study diffusion from the nucleus into the cytoplasm.
For the experiments reported here, we demonstrated that NP-GFP exited the nucleus at low tempera- tures even in the absence of metabolic inhibitors. Migration of NP-GFP into the cytoplasm of HeLa cells during chilling is not caused by irreversible damage of the cells or the nuclear envelope. HeLa cells survived this treatment, and the nuclear substrate was re- imported into nuclei after shifting to normal growth conditions. The rapid nuclear exit of NP-GFP during chilling enables us to study diffusion in the absence of metabolic inhibitors which are likely to interfere with a variety of cellular processes.
In addition to the analyses described above, NP- GFP will be useful as a tool to test how various drugs might interfere with diffusion across the nuclear envelope. The possible effect by these agents can be easily followed by fluorescence microscopy. Stable cell lines expression fluorescent reporter protein
We also studied diffusion of the fluorescent reporter protein in the stable cell line synthesizing nucleoplasmin-GFP. However, we did not detect an equilibration of the fluorescence signal between nucleus and cytoplasm if cells were chilled or treated with sodium azide/deoxyglucose. Two possible hypotheses which are not mutually exclusive could explain this result: (i) The larger size of nucleoplasmin-GFP as compared to NP-GFP prevents its rapid diffusion across the nuclear envelope, (ii) Nucleoplasmin-GFP still contains the DNA-binding region of Xenopus nucleoplasmin, and binding to DNA could retain the reporter protein in the nucleus even in the absence of active facilitated transport across the nuclear membrane. This cell line will therefore be useful for studies that concentrate on the analysis of nuclear transport only.
Additional cell lines expressing NP-GFP or only GFP have also been generated, and we are currently creating additional cell lines which have improved fluorescence . In general, all of the cell lines described will allow the controlled expression not only of the fluorescent reporter protein but also of additional genes of interest. Since the cells contain the tTA-element (Damke, H. et al . , 1995, Meth . Enzym. , 257:209-220), they can be used to regulate the synthesis of a protein of interest by addition of tetracycline to the growth medium. Genes encoded on a tetracycline response plasmid are repressed in the presence of tetracycline, whereas in the absence of tetracycline gene expression is induced.
Use of nuclear substrates in other mammalian cell lines and in the yeast S. cerev±s±ae Nuclear substrates described in this study were also tested in other mammalian cell lines such as COS-7 and CHO cells. Similar results as described for HeLa cells were obtained, indicating that the reporter system we have developed is useful as a model to study nuclear transport in different mammalian cells. Taken together, we have established tools to study diffusion and signal-mediated transport across the nuclear envelope in higher eukaryotic cells. This sets the stage to analyze nucleocytoplasmic traffic in living mammalian cells in more detail.
Expression of fluorescent reporter proteins described here is currently also analyzed in the yeast S. cerevisiae.
Analysis of nuclear transport in vitro
Histidine-tagged (His6) versions of fluorescent reporter proteins have been created. Synthesis of these proteins is inducible in Escherichia coli . Fusion proteins are currently purified by affinity-purifica- tion and analyzed in in vi tro nuclear transport assays. The advantage of these substrates is that they are easy to purify in large quantities and at low costs. Previously used substrates for in vi tro studies involved the synthesis and covalent coupling of NLS- peptides, an expensive and laborious procedure.
While the invention has been described in con- nection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

Claims

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows :
1. Genes encoding reporter proteins to monitor transport and passive diffusion of proteins across the nuclear envelope in mammalian cells, which comprises a protein carrying a nuclear localization sequence (NLS) fused to at least one copy of a reporter protein, wherein the reporter protein allows for the visualization of the reporter fusion protein.
2. The genes encoding proteins of claim 1, wherein the NLS is connected to the reporter protein via a linker sequence encoding small amino acid residues.
3. The genes encoding proteins of claim 2, wherein the NLS is derived from Xenopus laevis nucleoplasmin or present in the C-terminal portion of nucleoplasmin.
4. The genes encoding proteins of claim 3, wherein said reporter protein is a fluorescent protein.
5. The genes encoding proteins of claim 4, wherein said fluorescent protein is Aequorea victoria green fluorescent protein (GFP).
6. An expression vector to transiently and stably express reporter genes of claim 1, which comprises a gene encoding a protein carrying a nuclear localization sequence (NLS) fused to at least one copy of a reporter protein, wherein expression of the gene is under the control of an inducible promoter.
7. The expression vector of claim 6, wherein the NLS is connected to the reporter protein via a linker sequence encoding small amino acid residues.
8. The expression vector of claim 7, wherein the reporter protein is a fluorescent protein.
9. The expression vector of claim 8, wherein the fluorescent protein is Aequorea victoria green fluorescent protein (GFP).
10. A cell line stably expressing a nuclear reporter protein to monitor transport and passive diffusion of proteins across the nuclear envelope, which comprises a cell line transfected by the expression vector of claim 6.
11. The cell line of claim 10, wherein NLS is fused to reporter protein via a linker encoding small amino acid residue.
12. The cell line of claim 10, wherein said cell line is selected from the group consisting of HeLa, COS and CHO.
13. An in vivo assay for screening compounds which affect transport and/or passive diffusion of proteins across the nuclear envelope in mammalian cells, which comprises the steps of: a) treating a cell line of claim 10 with a compound; and b) visualizing the distribution of reporter protein in nuclei and cytoplasm.
14. An in vitro assay for screening compounds which affect transport and/or passive diffusion of proteins across the nuclear envelope in mammalian cells, which comprises the steps of: a) treating semi-permeabilized cells which support in vi tro nuclear transport with a compound and a protein of claim 1; and b) visualizing the distribution of reporter protein in nuclei and cytoplasm.
15. The assay of claim 14, wherein said cells can be treated with the compound and protein concurrently or one after the other.
PCT/CA1998/000385 1997-04-28 1998-04-24 Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport WO1998049325A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU70229/98A AU7022998A (en) 1997-04-28 1998-04-24 Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4491197P 1997-04-28 1997-04-28
US60/044,911 1997-04-28

Publications (1)

Publication Number Publication Date
WO1998049325A1 true WO1998049325A1 (en) 1998-11-05

Family

ID=21935000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1998/000385 WO1998049325A1 (en) 1997-04-28 1998-04-24 Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport

Country Status (2)

Country Link
AU (1) AU7022998A (en)
WO (1) WO1998049325A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018572A2 (en) * 2000-08-25 2002-03-07 Aventis Pharmaceuticals Inc Membrane penetrating peptides and uses thereof
WO2003044535A1 (en) * 2001-11-22 2003-05-30 Mehmet Ozturk Method, antigen and antibody for distinguishing viable and apoptotic cells
US7754678B2 (en) 2000-08-25 2010-07-13 Aventis Pharmaceuticals Inc. Membrane penetrating peptides and uses thereof
WO2016064742A1 (en) * 2014-10-21 2016-04-28 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Methods and compositions for screening molecular function comprising chimeric minimotifs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041228A2 (en) * 1996-05-01 1997-11-06 Pioneer Hi-Bred International, Inc. Use of the green fluorescent protein as a screenable marker for plant transformation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041228A2 (en) * 1996-05-01 1997-11-06 Pioneer Hi-Bred International, Inc. Use of the green fluorescent protein as a screenable marker for plant transformation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHATTERJEE S ET AL: "In vivo analysis of nuclear protein traffic in mammalian cells.", EXPERIMENTAL CELL RESEARCH, (1997 OCT 10) 236 (1) 346-50. JOURNAL CODE: EPB. ISSN: 0014-4827., United States, XP002076915 *
PTUSHKINA M ET AL: "Intracellular targeting and mRNA interactions of the eukaryotic translation initiation factor eIF4E in the yeast Saccharomyces cerevisiae.", BIOCHIMICA ET BIOPHYSICA ACTA, (1996 AUG 14) 1308 (2) 142-50. JOURNAL CODE: A0W. ISSN: 0006-3002., Netherlands, XP002076911 *
SCHREIBER V ET AL: "A eukaryotic expression vector for the study of nuclear localization signals.", GENE, (1994 DEC 15) 150 (2) 411-2. JOURNAL CODE: FOP. ISSN: 0378-1119., Netherlands, XP002076913 *
SHIVANI CHATTERJEE ET AL.: "Monitoring nuclear transport in HeLa cells using the green fluorescent protein", BIOTECHNIQUES., vol. 21, no. 1, July 1996 (1996-07-01), NATICK US, pages 62 - 63, XP002076910 *
WEIS K ET AL: "The conserved amino-terminal domain of hSRP1 alpha is essential for nuclear protein import.", EMBO JOURNAL, (1996 APR 15) 15 (8) 1818-25. JOURNAL CODE: EMB. ISSN: 0261-4189., ENGLAND: United Kingdom, XP002076912 *
WERNER BARTH ET AL.: "The yeast nucleoporin Nsp1 binds nuclear localization sequences in vitro", BIOCHEMISTRY AND CELL BIOLOGY, vol. 74, no. 3, 1996, pages 363 - 372, XP002076914 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018572A2 (en) * 2000-08-25 2002-03-07 Aventis Pharmaceuticals Inc Membrane penetrating peptides and uses thereof
WO2002018572A3 (en) * 2000-08-25 2003-09-12 Aventis Pharma Inc Membrane penetrating peptides and uses thereof
US7754678B2 (en) 2000-08-25 2010-07-13 Aventis Pharmaceuticals Inc. Membrane penetrating peptides and uses thereof
WO2003044535A1 (en) * 2001-11-22 2003-05-30 Mehmet Ozturk Method, antigen and antibody for distinguishing viable and apoptotic cells
WO2016064742A1 (en) * 2014-10-21 2016-04-28 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Methods and compositions for screening molecular function comprising chimeric minimotifs

Also Published As

Publication number Publication date
AU7022998A (en) 1998-11-24

Similar Documents

Publication Publication Date Title
KR0176966B1 (en) Functional recombinantly prepared synthetic protein polymer
KR0144861B1 (en) Receptor Protein for Human B Cell Stimulator-2
Way et al. Expression of human plasma gelsolin in Escherichia coli and dissection of actin binding sites by segmental deletion mutagenesis.
Choidas et al. The suitability and application of a GFP-actin fusion protein for long-term imaging of the organization and dynamics of the cytoskeleton in mammalian cells
Chin et al. Transfected rat high-molecular-weight neurofilament (NF-H) coassembles with vimentin in a predominantly nonphosphorylated form
US6184348B1 (en) Functional recombinantly prepared synthetic protein polymer
Bosnali et al. Generation of transducible versions of transcription factors Oct4 and Sox2
JPS61500251A (en) heteropolymer-based protein
Gimona et al. Specificity of dimer formation in tropomyosins: influence of alternatively spliced exons on homodimer and heterodimer assembly.
Waterman et al. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants
EP0874903A1 (en) Humanized green fluorescent protein genes and methods
CN108300736B (en) CHO cell strain for efficiently expressing recombinant human beta-NGF-Fc fusion protein and construction method thereof
JPH05507411A (en) Expression of the BMP-2 family by mammals
US8993742B2 (en) Tubulo-vesicular structure localization signals
EP3673053A1 (en) Improved transposase polypeptide and uses thereof
EP0877802A1 (en) NEUROGENIC DIFFERENTIATION (NeuroD) GENES AND PROTEINS
CA2980819C (en) System for the presentation of peptides on the cell surface
WO1998049325A1 (en) Reporter fusion proteins, expression vectors and transfected cell lines thereof for the analysis of nuclear transport
JP3844656B2 (en) Methods for transformation of animal cells
Chatterjee et al. In VivoAnalysis of Nuclear Protein Traffic in Mammalian Cells
CA2328506A1 (en) Modifying the expression of the fsh beta gene by homologous recombination
CN110305905B (en) Mouse Tmem240 recombinant eukaryotic expression plasmid, lentivirus and construction method
Strandmann et al. The bifunctional protein DCoH/PCD, a transcription factor with a cytoplasmic enzymatic activity, is a maternal factor in the rat egg and expressed tissue specifically during embryogenesis.
US20050208533A1 (en) Modulators of morphogen expression and methods of identifying the same
Hu et al. Targeting the Escherichia coli lac repressor to the mammalian cell nucleus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998546432

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA